Hosted on MSN3mon
Clinical trial suggests new drug candidate for spinocerebellar ataxia may offer certain therapeutic benefits
Spinocerebellar ataxia (SCA ... a group of disorders caused by proteins with abnormal long polyglutamine (polyQ) tracts. These proteins accumulate within nerve cells, forming aggregates that ...
Hosted on MSN11mon
Scientists use an innovative approach to provide relevant insights into a rare neurologic disorder
Spinocerebellar ataxia type 37 is a rare neurological disorder originally found in patients from the Iberian Peninsula. It starts in adulthood and gradually worsens, causing speech difficulties ...
Nature28d
Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1
Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder caused by expansion of a polyglutamine tract in ataxin-1. In affected neurons of SCA1 patients and ...
Morningstar23d
Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia
Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. Troriluzole demonstrated a 50-70% slowing of SCA disease progression on the ...